Advaxis Stock Analysis (NASDAQ:ADXS)

Add to My Stocks
$6.87 $0.08 (1.18%) ADXS stock closing price Jul 25, 2017 (Closing)
Watch Robo Advisor Video of ADXS Stock Analysis
Advaxis
Updated on : Jul 25, 2017
previous close
ADXS 6.9 (0%)
S&P 500 2477.1 (0%)
Closing Price On: Jul 25, 2017
stock rating
RATING: ★★★★★★★★★★ (0/5)
Industry :
Medical-Biomed-Genetics
Sector :
Medical
5 Quarter Revenue
Revenue Growth
2017-Q2
$million
%
YOY GROWTH
Compared to the industry
Operating Profit
Operating Margin:
-718.9%
Sector Average:
-0.5%
5 Quarter Net Profit
Net Margins
2017-Q2
%
LTM Margin
Debt/Equity Ratio
Debt:
0.3M
Debt/Equity Ratio:
 0
Compared to the industry
Cash Flow
Operating cash flow:
-$19.5M
Net Income:
-$20.5M
PROS      CONS
Low Debt Burden
Recent Growth
Operating Margins
Net Margins
ROE
FCF Margin
PS Valuation
Rating: ★★★★★★★★★★ (0/5)
Relative Valuation
ADXS PS : :
25.3
Industry PS : :
5.3
Other Metrics
Return on Equity:
-76.2%
Free Cash Flow Margin:
-602.9%
Double Tap To Exit Full Screen
0:00
/

Advaxis Analysis Video

152 5 2

View Advaxis stock analysis video. This is our ADXS analyst opinion covering the buy and sell arguments for ADXS stock.

Advaxis, Inc. Stock Rating (1.2/5)

Our Advaxis stock opinion is based on fundamentals of the company. This Advaxis stock analysis is based on latest Q2 earnings for 2017. The stock price analysis takes into account a company's valuation metrics.

Should you buy ADXS stock?

  • With its debt/equity ratio of  0, Advaxis has a lower debt burden when compared to the Medical average.

Should you sell ADXS stock?

  • Advaxis revenue saw a decline of -999% YoY in 2017 Q2.
  • Advaxis registered a negative operating margin of -718.9% (average) over the Trailing Twelve Months (TTM).
  • Advaxis posted an average Net loss of -691.1% in the last twelve months.
  • The company is trading at a price to sales multiple of 25.3, which is overvalued in comparison to the Medical-Biomed-Genetics industry average multiple of 5.3.
  • A negative ROE of -76.2% indicates that the company is not able to generate profits with the money shareholders have invested.
  • The company has negative Free Cash Flows (FCF), with a negative FCF margin of -602.9%.

Comments on this video and Advaxis stock